Entera Bio Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ENTX in the last 7 days.
No SEC Form 4 filings for $ENTX in the last 30 days.
See all $ENTX insider activity →Entera Bio (ENTX) raised $275M in an oversubscribed private placement, funding Phase 3 trials for EB613, its oral osteoporosis treatment, and extending its cash runway to 2030. Shares rose despite dilution concerns, with BVF Partners leading the investment. The FDA accepted the Phase 3 protocol, and analysts project a loss for Q2 2024 with a $9 price target.
Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.
Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Entera Announces Second Quarter 2026 Financial Results and Business Updates U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women wi
Recent ENTX coverage spans corporate actions, earnings and market movers.
The large capital raise strengthens the balance sheet and de‑risks near‑term financing, likely supporting short‑term price upside.
Fresh capital plus FDA-aligned Phase 3 design reduces near-term financing risk, but the earnings miss and widening loss can pressure sentiment until investors focus on EB613 execution.
FDA alignment and a defined Phase 3 path for EB613 reduce regulatory uncertainty and improve the probability-weighted timeline for an NDA submission.
This is a new beneficial-ownership disclosure that can shift perceived control and liquidity risk, but it does not indicate an operational catalyst.
The PIPE provides multi-year funding visibility through Phase 3 registrational studies, reducing near-term financing risk.
AlphAI scores every news story that mentions ENTX with an AI model for sentiment and relevance, and aggregates insider trades from Entera Bio Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Entera Bio (ENTX) raised $275M in an oversubscribed private placement, funding Phase 3 trials for EB613, its oral osteoporosis treatment, and extending its cash runway to 2030. Shares rose despite dilution concerns, with BVF Partners leading the investment. The FDA accepted the Phase 3 protocol, and analysts project a loss for Q2 2024 with a $9 price target.
3 min readEntera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.
7 min readEntera Bio Ltd. (ENTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Entera Announces Second Quarter 2026 Financial Results and Business Updates U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women wi
6 min readEntera Bio Ltd. (ENTX) disclosed in an SEC Schedule 13G that Longitude Venture Partners V, L.P. (via Longitude Capital Partners V, LLC and its managing members) is the record holder of 7,843,138 ordinary shares, or 4.6% of 172,251,411 shares outstanding as of July 28, 2026. The filing also references Seven Fleet’s potential 4.1% beneficial ownership.
3 min readGreenberg Traurig advised Entera Bio Ltd. (NASDAQ: ENTX) on an oversubscribed $275 million private placement PIPE. The company said the proceeds extend its cash runway into 2030 and fund Phase 3 registrational studies for EB613, an oral PTH (1-34) peptide tablet for osteoporosis. Arx Capital Markets data cited the deal as a record Israeli biotech PIPE.
2 min readEntera Bio (ENTX) shares rose after the company priced a large securities offering to fund EB613’s Phase 3 osteoporosis program. Entera said the financing should extend its cash runway into 2030 and support planned FDA application. It will sell 122.96M shares at $2.04 and pre-funded warrants for up to 11.84M shares. Analysts expect an Aug. 11 loss of 8 cents/share.
6 min readEntera Bio Ltd. (ENTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 exhibit_10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 26, 2026, between Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), and each
6 min readBiotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.
6 min readEntera Bio (Nasdaq: ENTX) said it raised $275 million via a private placement, led by BVF Partners, to fund operations through 2030, including a Phase III osteoporosis trial for its lead oral drug. The company said success would support an FDA marketing-approval application. Shares were priced at $2.04 and later traded around $3.57.
4 min readBiotech stocks rose on multiple catalysts. CareDx (CDNA) jumped 35.6% after Medicare finalized an LCD covering its transplant molecular testing, effective Aug. 30, 2026. AtaiBeckley (ATAI) gained 33.4% on an Eli Lilly (LLY) acquisition deal up to $3.8B. Abbott (ABT) rose 10.7% after Q2 results and raised FY26 adjusted EPS outlook to $5.45-$5.60.
7 min read
